What We Monitor for Combination Products
Lead center designation updates
OCP jurisdiction guidance
Pre-RFD meeting protocols
Cross-labeling requirements
GMP/QSR harmonization
Clinical trial design (multi-arm)
PMA/NDA coordination
Post-market surveillance (dual)
Combination-specific warning letters
Decisions This Intelligence Affects
Regulatory Strategy
- • Lead center selection rationale
- • Pre-RFD meeting preparation
- • Submission sequencing decisions
- • Labeling coordination strategy
Quality Systems
- • Dual GMP/QSR compliance
- • Manufacturing integration
- • Supplier qualification (both)
- • Change control coordination
Clinical Development
- • Study design (combination arms)
- • Endpoint selection strategy
- • Comparator considerations
- • Risk-benefit documentation
Commercial & Legal
- • Promotional claim boundaries
- • Liability allocation strategy
- • Partner agreement structures
- • Reimbursement positioning
How Combination Product Teams Use This Intelligence
Navigate Lead Center Shifts
Anticipate OCP jurisdiction changes before they affect your program
Coordinate Dual Submissions
Align drug and device components with current expectations
Reduce Complexity Delays
Pre-interpreted guidance saves weeks of cross-team analysis
Avoid Cross-Labeling Issues
Stay ahead of labeling coordination requirements
Strengthen RFD Rationale
Build defensible lead center justifications
Document Regulatory Decisions
Support combination strategy with current precedent